Iqvia Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Iqvia Holdings Inc (IQV) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Iqvia Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 16,632M vs 519,996M combined for tracked competitors (3.1% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-0.2% annualized vs trailing 12 months), vs holding steady (+0.0%) for its tracked peer group.
- Growth: Iqvia Holdings Inc generated 8.4% revenue growth year over year in Q1 2026, vs 4.7% for its tracked competitors combined.
- Profitability: Its 6.6% net margin compares with 10.9% for the peer group.
- Scale: Iqvia Holdings Inc ranks #2 of 47 companies by market capitalization in the Medical Laboratories industry, holding 13.2% of industry market cap.
- Peer revenue share: Iqvia Holdings Inc accounted for 3.1% of combined revenue among its tracked peer group, up from 3.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.18M compares with $0.84M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IQV Sales vs. its Competitors, Q1 2026
Iqvia Holdings Inc reported revenue growth of 8.41 % year on year in Q1 2026, above its competitors' combined revenue growth of 4.68 %.
With a net margin of 6.62 %, Iqvia Holdings Inc reported lower profitability than its competitors (10.86 %).
Iqvia Holdings Inc generated 3.09 % of the combined sales of its peer group, up from 2.99 % a year earlier.
Iqvia Holdings Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Iqvia Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Iqvia Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (16) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Iqvia Holdings Inc's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 5.7% year over year, combined, vs 8.4% for Iqvia Holdings Inc. Iqvia Holdings Inc's share of combined industry revenue moved from 7.04% to 7.22%, a gain of 0.18 percentage points.
Iqvia Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Iqvia Holdings Inc | Yes | Yes | Yes | Yes |
| Competitors combined (15) | ||||
| High-Confidence Competitors (23) | ||||
| Similar-Size Competitors (6) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IQV Stock Performance relative to its Competitors
IQV Stock Performance relative to High-Confidence Competitors
IQV Stock Performance relative to Similar-Size Competitors
IQV Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Charles River Laboratories International inc | 282.9% | Outperformed |
| 2 | Nrc Health | 282.9% | Outperformed |
| 3 | Medpace Holdings Inc | 282.9% | Outperformed |
| 4 | Labcorp Holdings Inc | 282.9% | Outperformed |
| 5 | Frontier Communications Parent Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Iqvia Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Iqvia Holdings Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Iqvia Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Iqvia Holdings Inc | 46,010.71 | 16,632.00 |
| Verizon Communications Inc | 194,702.28 | 138,895.00 |
| T mobile Us Inc | 183,436.76 | 90,530.00 |
| At and t Inc | 173,094.32 | 127,239.00 |
| Comcast corporation | 77,790.30 | 124,904.00 |
| Veeva Systems Inc | 46,209.36 | 3,456.71 |
| SUBTOTAL | 795,146.04 | 549,276.94 |
Sign in to see all competitors of Iqvia Holdings Inc .
Sources: Iqvia Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Iqvia Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Iqvia Holdings Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Veeva | Named by the company | 85% |
| Medpace Holdings Inc | Named by the company | 85% |
| Labcorp Drug Development | Named by the company | 85% |
| Nielsen | Named by the company | 85% |
| Panalgo | Named by the company | 85% |
| Accenture | Named by the company | 85% |
| Relx | Named by the company | 85% |
| CompuGroup Medical | Named by the company | 85% |
| ZS Associates | Named by the company | 85% |
| Deloitte | Named by the company | 85% |
| Infosys | Named by the company | 85% |
| Medidata | Named by the company | 85% |
| Optum Insight | Named by the company | 85% |
| PPD | Named by the company | 85% |
| Forian Inc | Named by the company | 85% |
| Cerner | Named by the company | 85% |
| UnitedHealth Group | Named by the company | 85% |
| Datavant | Named by the company | 85% |
| Press Ganey | Named by the company | 85% |
| GfK | Named by the company | 85% |
| LexisNexis Risk Solutions | Named by the company | 85% |
| NielsenIQ | Named by the company | 85% |
| Parexel International Corporation | Named by the company | 85% |
| Aetion | Named by the company | 85% |
| Tempus | Named by the company | 85% |
| Covance Inc. | Named by the company | 85% |
| Lifemd Inc | Named by the company | 85% |
| Evidera | Named by the company | 85% |
| Kantar Health | Named by the company | 85% |
| Merative | Named by the company | 85% |
| Oracle | Named by the company | 85% |
| PRA Health Sciences | Named by the company | 85% |
| Icon Plc | Named by the company | 85% |
| Cognizant Technology Solutions | Named by the company | 85% |
| Definitive Healthcare | Named by the company | 85% |
| RTI Health Solutions | Named by the company | 85% |
| IBM | Named by the company | 85% |
| McKinsey | Named by the company | 85% |
| Norstella | Named by the company | 85% |
| Pharmaceutical Product Development, Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Iqvia Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Iqvia Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Iqvia Holdings Inc | Research and Development Solutions 58.90 % |
| Verizon Communications Inc | Verizon Consumer Group 76.61 % |
| T mobile Us Inc | Wireless 100.00 % |
| At and t Inc | Advanced Connectivity 90.37 % |
| Comcast corporation | Residential Connectivity and Platforms 57.19 % |
| Veeva Systems Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Iqvia Holdings Inc .
Iqvia Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Iqvia Holdings Inc | 46,011 | 178,839 | 14,914 |
| Verizon Communications Inc | 194,702 | 1,544,994 | 184,638 |
| T mobile Us Inc | 183,437 | 1,207,067 | 140,573 |
| At and t Inc | 173,094 | 956,468 | 173,074 |
| Comcast corporation | 77,790 | 697,788 | 60,145 |
| Veeva Systems Inc | 46,209 | 436,013 | 127,998 |
| PEERS TOTAL | 749,135 | 843,691 | 95,297 |
Sign in to see all peers for Iqvia Holdings Inc .
Iqvia Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Iqvia Holdings Inc | Americas 48.17 % |
| Veeva Systems Inc | North America 59.57 % |
| Charles River Laboratories International inc | United States 54.61 % |
| Zoominfo Technologies Inc | Non-US 12.96 % |
| Inotiv Inc | United States 88.12 % |
| Level 3 Parent Llc | North America 97.89 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Iqvia Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 42 companies in Iqvia Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Iqvia Holdings Inc ranks #2 of 42 companies by market capitalization in its industry, holding 13.16 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 859, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Natera Inc | 58,998 | 16.87 % |
| 2 | Iqvia Holdings Inc | 46,011 | 13.16 % |
| 3 | Ge Healthcare Technologies Inc | 30,518 | 8.73 % |
| 4 | Quest Diagnostics Inc | 26,613 | 7.61 % |
| 5 | Incyte Corporation | 1,234 | 5.2% |
| 6 | Labcorp Holdings Inc | 1,234 | 5.2% |
| 7 | Guardant Health Inc | 1,234 | 5.2% |
| 8 | Koninklijke Philips Nv | 1,234 | 5.2% |
| 9 | Medpace Holdings Inc | 1,234 | 5.2% |
| 10 | Charles River Laboratories International inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Iqvia Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Iqvia Holdings Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Natera Inc | 58,998 | 151.24 % |
| 2 | Iqvia Holdings Inc | 46,011 | 52.12 % |
| 3 | Ge Healthcare Technologies Inc | 30,518 | -6.90 % |
| 4 | Quest Diagnostics Inc | 1,234 | 12.3% |
| 5 | Incyte Corporation | 1,234 | 12.3% |
| 6 | Labcorp Holdings Inc | 1,234 | 12.3% |
| 7 | Guardant Health Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Iqvia Holdings Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Iqvia Holdings Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (58 companies). See the full Medical Laboratories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 32.99 % | 43.57 % (avg) | -10.6 pp |
| Operating Margin | 13.23 % | industry median | +39.2 pp |
| EBITDA Margin | 18.99 % | -4.90 % (avg) | +23.9 pp |
| Capital Intensity (Capex / Revenue) | 3.54 % | 9.54 % (avg) | -6.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Iqvia Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (58 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Laboratories industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 21.4x | 37.0x | -15.5x |
| EV / EBITDA | 13.5x | 18.0x | -4.5x |
| P/B | 4.7x | 2.9x | +1.8x |
| Return on Equity | 22.15 % | industry aggregate | 13.15 % |
| Return on Invested Capital | 7.44 % | -4.04 % (avg) | 11.48 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Iqvia Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | 6.49 % | 2.44 % | 22.14 % | 3.86 % | 3.98 % | 2.81 % | 5.87 % |
| Operating Margin | 7.12 % | 7.01 % | 6.44 % | 10.04 % | 12.48 % | 13.19 % | 14.29 % | 13.38 % |
| Return on Invested Capital | 2.72 % | 2.94 % | 2.83 % | 5.49 % | 7.18 % | 7.77 % | 8.30 % | 7.50 % |
| P/E | 97.0x | 156.4x | 123.7x | 52.5x | 37.3x | 29.2x | 27.1x | 29.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Iqvia Holdings Inc's Strategic Group Map
Every company in Iqvia Holdings Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Iqvia Holdings Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Iqvia Holdings Inc's BCG Growth-Share Matrix
Relative market share (vs Iqvia Holdings Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Iqvia Holdings Inc falls in the Dog quadrant: relative market share of 0.78x vs its largest competitor, in an industry growing revenue 5.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Iqvia Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 859 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.54 % vs industry average 9.54 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Iqvia Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Iqvia Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Iqvia Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Iqvia Holdings Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Iqvia Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 39.2 points above the industry median.
- Return on equity 13.2 points above the industry aggregate.
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Trades at a lower P/E than the industry average (21.4x vs 37.0x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Iqvia Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Iqvia Holdings Inc | 0.24 | 0.76 | 2.47 |
| Verizon Communications Inc | 0.15 | 0.72 | 1.52 |
| T mobile Us Inc | 0.25 | 1.04 | 1.42 |
| At and t Inc | 0.32 | 0.95 | 1.10 |
| Comcast corporation | 0.27 | 0.86 | 1.27 |
| Veeva Systems Inc | 1.18 | 5.42 | - |
Sign in to see all peers for Iqvia Holdings Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Iqvia Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Iqvia Holdings Inc | Q1 2026 | +8.4 % | +10.4 % |
| Verizon Communications Inc | Q2 2026 | -0.7 % | -22.9 % |
| T mobile Us Inc | Q1 2026 | +10.6 % | -15.2 % |
| At and t Inc | Q2 2026 | +2.3 % | +3.1 % |
| Comcast corporation | Q2 2026 | -1.2 % | -69.0 % |
| Veeva Systems Inc | Q2 2026 | +17.6 % | +36.5 % |
| PEERS TOTAL | +2.1 % | -38.0 % |
Sign in to see all peers for Iqvia Holdings Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Iqvia Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Iqvia Holdings Inc | Q1 2026 | +10.5 % | -10.6 % |
| Verizon Communications Inc | Q2 2026 | - | +29.6 % |
| T mobile Us Inc | Q1 2026 | +28.7 % | +5.0 % |
| At and t Inc | Q2 2026 | -1.7 % | +16.4 % |
| Comcast corporation | Q2 2026 | - | +5.3 % |
| Veeva Systems Inc | Q2 2026 | +19.0 % | +27.3 % |
Sign in to see all peers for Iqvia Holdings Inc .
Iqvia Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Iqvia Holdings Inc | 4.74% | 5.95% | 22.15% |
| Verizon Communications Inc | 4.10% | 5.08% | 15.74% |
| T mobile Us Inc | 4.88% | 7.63% | 17.82% |
| At and t Inc | 5.44% | 5.04% | 18.23% |
| Comcast corporation | 4.05% | 5.22% | 11.56% |
| Veeva Systems Inc | 11.51% | 13.75% | 14.00% |
Sign in to see all peers for Iqvia Holdings Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Iqvia Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Iqvia Holdings Inc | 33.70 | 2.77 |
| Verizon Communications Inc | 11.82 | 1.40 |
| T mobile Us Inc | 17.75 | 2.03 |
| At and t Inc | 8.28 | 1.36 |
| Comcast corporation | 7.23 | 0.62 |
| Veeva Systems Inc | 45.97 | 13.37 |
| PEERS AVERAGE | 12.92 | 1.45 |
Sign in to see all peers for Iqvia Holdings Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.